Serplulimab Approved by NMPA for Perioperative Gastric Cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy
Dr. Jason Zhu, Executive Director and CEO of Henlius, stated:“The approval of serplulimab for perioperative gastric cancer marks another major milestone for Henlius as we continue to drive innovation based on ‘first principles’ and deepen our presence in gastrointestinal oncology. Centered on patient needs, this new post-operative chemotherapy-free regimen not only underscores our strong expertise in tumor immunotherapy, but also brings new hope for cure to patients undergoing perioperative treatment for gastric cancer. Looking ahead, we will continue to unlock the clinical potential of our innovative pipeline and accelerate our Globalization 2.0 strategy, with the goal of delivering high-quality innovative biologic medicines to benefit patients in China and around the world.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data